BiotechTube

Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carotid Atherosclerosis

Conditions

Carotid Atherosclerosis

Trial Timeline

Apr 1, 2009 → Oct 1, 2010

NCT ID
NCT00804843

About Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin

Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin is a phase 2 stage product being developed by Merck for Carotid Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00804843. Target conditions include Carotid Atherosclerosis.

What happened to similar drugs?

3 of 6 similar drugs in Carotid Atherosclerosis were approved

Approved (3) Terminated (1) Active (2)
✅Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
✅Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
✅EvolocumabAmgenApproved
🔄RosuvastatinAstraZenecaPhase 3
❌Rimonabant + Placebo (for Rimonabant)SanofiPhase 3
🔄Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00804843Phase 2Completed

Competing Products

9 competing products in Carotid Atherosclerosis

See all competitors
ProductCompanyStageHype Score
AbciximabEli LillyPhase 1/2
24
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
39
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
43
simvastatin + placeboMerckPre-clinical
26
EvolocumabAmgenApproved
39
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Rimonabant + Placebo (for Rimonabant)SanofiPhase 3
32
Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3
37